# Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

> **NCT01438814** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 689 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** metformin placebo
- **DRUG:** linagliptin placebo
- **DRUG:** metformin
- **DRUG:** metformin
- **DRUG:** linagliptin

## Key facts

- **NCT ID:** NCT01438814
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 689 (ACTUAL)
- **Last updated:** 2014-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438814, "Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01438814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*